Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
NCT04555304 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 15, 2020
- Completion date
- January 15, 2022
- Enrollment
- 81 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
gastric cancer, gastroesophageal cancer